Therefore, we aimed to determine whether GLP-1RAs, compared with sodium–glucose cotransporter 2 (SGLT2) inhibitors, metformin or other second- or third-line glucose-lowering medications, are associated with a lower rate of new-onset adverse cardiovascular events (CVEs) among patients with NAFLD and type 2 diabetes. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.